Trial Profile

A study comparing two treatment strategies Eribulin followed by BEV + PTX versus BEV + PTX followed by Eribulin and Effect of Bevacizumab and Eribulin for metastatic breast cancer in the real world evaluated using the propensity score matching analysis (PSMA) and inverse probability of treatment weighting analysis (IPTWA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2020 New trial record
14 Dec 2019 Results comparing two treatment strategies, Eribulin followed by Bevacizumab (BEV) + Paclitaxel (PTX) versus BEV + PTX followed by Eribulin and evaluating efficacy of Eribulin, presented at the 42nd Annual San Antonio Breast Cancer Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com